A study published in Neurology involving people over age 80 shows that the presence of Alzheimer’s disease biology can identify patients at greater risk of progressing to dementia, even when initial cognitive differences are subtle.

The use of biomarkers, particularly blood-based biomarkers such as p-Tau217, improves diagnostic accuracy in a population in which clinical assessment is limited by the coexistence of multiple conditions.

The arrival of new drugs that slow disease progression reinforces the need for earlier and more accurate diagnosis, including in older patients who could benefit from these therapies.

This Brain Medicine mini-review gathers a decade of converging research on plasma neurofilament light chain (NfL), a protein shed from injured neurons that has become a leading blood-based window onto neuronal damage in Alzheimer’s disease. Synthesizing existing studies rather than reporting new experiments, the authors trace how rising NfL tracks cognitive decline, brain atrophy, and disease progression. Their central argument concerns biological sex. The analysis concludes that an identical NfL level may reflect a more advanced process in men than in women, making sex-specific interpretation a clinical necessity rather than a refinement.

Specific GABAergic interneuron subtypes are the earliest to be affected by the amyloid plaque that causes Alzhemier’s Disease (AD). Dysfunctional GABAergic activity disrupts resting state gamma oscillations. Together, these dysfunctions result in impaired memory and cognition. Interventions that restore GABAergic activity and reinforce gamma oscillations can provide protective effects against AD-related pathology, and provide cognitive benefits to patients. Greater research into these approaches could benefit millions of patients.

This study revealed the complete molecular mechanism by which P.g induced microglial ferroptosis through the NOX4/PPAR-α/PGC-1α pathway, thereby driving neuroinflammation and cognitive impairment, providing a molecular target and theoretical basis for drug repurposing targeting NOX4 to intervene in periodontitis-associated Alzheimer's disease.